Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Type 2 diabetes mellitus, being diagnosed according to the 1999 WHO criteria for at least 3 months~2. Age ≥ 18 years~3. BMI ≥ 25.0 kg/m2~4. HbA1c ≥ 7.0 %~5. Treatment with insulin with stable dose of at least 30 U/day (± 4 U/day), for at least 75 days~Exclusion Criteria:~1. Prior or current use of any PPAR-γ agonist~2. Recent use (\< 3 months) of an investigational drug~3. Pre-existing medical condition judged to preclude safe participation in the study~4. Contraindication/intolerance to study medication~5. Use of any drug which in the Investigator's opinion could interfere with the glucose level (e.g. systemic corticosteroids)~6. Diagnosed or receiving medication for heart failure, NYHA I to IV~7. Hospitalisation for a major CV event in the last 3 months, scheduled major CV intervention~8. Uncontrolled treated/untreated systolic blood pressure \>180 mmHg and/or diastolic blood pressure \> 95 mmHg~9. Known diabetic macular oedema~10. Hematuria~11. Serum creatinine \>130 μmol/l~12. ALT, AST, total bilirubin or alkaline phosphatase ≥ 2.5 times the upper limit of normal~13. Haemoglobin significantly (in the Investigators opinion, but not more than 1 mmol/L) below the lower limit of normal or haemoglobinopathy interfering with valid HbA1c assay~14. Pregnancy, breast feeding or planning pregnancy or not using adequate contraceptive methods (adequate contraceptive measures are an intrauterine device or oral contraceptives)~15. Mental incapacity, unwillingness, or language barrier precluding adequate understanding or cooperation~16. Abuse of alcohol or drugs, or presence of any condition that in the Investigators opinion may lead to poor adherence to study protocols~17. Cancer or any clinically significant disease or disorder, except for conditions associated to the type 2 diabetes, which in the Investigator's opinion could interfere with the results of the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Balaglitazone 10 mg per day (Type: EXPERIMENTAL): None
- Balaglitazone 20 mg per day (Type: EXPERIMENTAL): None
- Pioglitazone 45 mg per day (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).